Primer Capital's porfolio project, raises €7M in addtion to its Series B6 November 2019 Paris, November 6th, 2019
Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including acute ischemic stroke, today announced that it has raised €7 million in addition to its Series B which is now completed at €22,3 million.
New financing will enable the company to expand in the US its phase II clinical trial ACTIMIS for its drug candidate glenzocimab (ACT017) in acute ischemic stroke.
“When we invested in this biotech last year, we have already seen a great potential of the company recognizing its innovativeness and uniqueness within its niche. Our initial assessment has turned out to be correct, since within such a short time the drug has made a huge leap forward raising one round of financing after another while demonstrating tremendous progress in research area ”, - commented Primer Capital COO Elizaveta Rozhdestvenskaya.
Read the full release here.